Cyclic β-(1, 2)-glucan blended poly DL lactic co glycolic acid (PLGA 10:90) nanoparticles for drug delivery

• Published in: Heliyon Vol. 5; no. 9; p. e02289
• Main Authors: Venkatachalam, Geetha, Venkatesan, Nandakumar, Suresh, Ganesan, Doble, Mukesh
• Format: Journal Article
• Language: English
• Published: England Elsevier Ltd 01.09.2019; Elsevier
• Subjects: Biomedical engineering; Blends; Cyclic β-(1, 2)-glucan; Drug delivery; Gentamicin; Materials science; PLGA; Polymers; PLGA; Blends; Gentamicin; Materials science; Drug delivery; Polymers; Cyclic β-(1, 2)-glucan; Biomedical engineering
• ISSN: 2405-8440; 2405-8440
• DOI: 10.1016/j.heliyon.2019.e02289

Our group had previously reported the encapsulation efficiency of cyclic β-(1, 2)-glucan for various drugs. The current study is aimed at evaluating the use of glucan as a drug carrier system by blending with poly lactic-co- glycolic acid (L:G = 10:90). Nanoparticles of glucan (0.5, 5, 10 and 20 wt %) blended with PLGA and gentamicin were synthesized. Encapsulation efficiency was higher for the blends (93% with 20 wt % of glucan) than the PLGA alone (79.8%). The presence of glucan enhanced both the biodegradability, and biocompatibility of PLGA. Degradation of the nanoparticles in vitro, was autocatalytic with an initial burst release of active drug and the release profile was modeled using the Korsmeyer-Peppas scheme. In vivo studies indicated that the drug released from the blends had high volume of distribution, and greater clearance from the system. Pharmacokinetics of the drug was predicted using a double exponential decay model. Blending with PLGA improved the drug release characteristics of the cyclic β-(1, 2)-glucan.